This association of activated non-canonical NF-kB signalling with poor outcome is corroborated by key survival analyses from a multicentre study, which showed that CLL patients with BIRC3 mutations (and therefore increased non-canonical NF-kB signalling), represent a group of patients with shorter progression-free survival [12]. Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.